FDA Approves Journavx: A Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
GHealth News - The U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine), a groundbreaking 50mg oral tablet, as a first-in-class non-opioid analgesic for managing moderate to severe acute pain in adults. This new treatment works by targeting pain-signaling pathways in the peripheral nervous system, blocking pain signals before they reach the brain.
Journavx is the first drug in this innovative class of pain management medications, offering an important alternative to opioid-based treatments. The FDA's approval is part of ongoing efforts to encourage the development of non-opioid pain treatments and reduce reliance on opioids.
The efficacy of Journavx was established in two clinical trials, showing significant pain reduction in patients following abdominoplasty a...